Primary resistance to BCMA-targeted bispecifi...

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA ...  Show more

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-ce ...  Show more

This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.

In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.

Co ...

In this continuation of our myeloma series, we discuss the progression of MGUS & smoldering myeloma to multiple myeloma. We also outline how to risk stratify a patient with multiple myeloma and gauge their response to treatment.  ...

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...